• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Course of COVID-19 in European Children: ICU Admissions, Risk Factors, and Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Götzinger et al. (The Lancet, 2020) described COVID-19 cases in children across Europe with a focus on risk factors and outcomes  

METHODS:

  • Multi-center cohort study
  • Setting
    • 82 health-care institutions across 25 European countries between April 1 and April 24 (peak of European pandemic)
    • Used Paediatric Tuberculosis Network European Trials Group (ptbnet), an established research network of mostly pediatric infectious disease specialists and pulmonologists
  • Participants
    • All individuals ≤18 years with RT-PCR confirmed SARS-CoV-2 infection
  • Study design
    • The authors examined outcomes as well as factors associated with
      • Need for ICU admission
      • Initiation of drug treatment for COVID-19

RESULTS:

  • 582 children included
    • Median age: 5.0 years (IQR 0.5 to 12.0)
    • Sex ratio: 1.15 males per female
    • Pre-existing medical condition: 25% (145 patients)
  • ICU admission: 8% (48 patients)
  • Mechanical ventilation: 4% (25 patients)
    • Inotropic support: 3% (19 patients)
    • Extracorporeal membrane oxygenation: <1% (1 patient)
    • Median duration: 7 days (IQR 2 to 11, range 1 to 34)
  • Risk factors for ICU admission
    • Being younger than 1 month: Odds ratio (OR) 5.06 (95% CI, 1.72 to 14. 87; p=0.0035)
    • Male sex: OR 2.12 (95% CI 1.06 to 4.21; p=0.033)
    • Pre-existing medical conditions: OR 3.27 (95% CI, 1.67 to 6.42; p=0.0015)
    • Presence of lower respiratory tract infection signs or symptoms at presentation: OR 10.46 (95% CI, 5.16 to 21.23; p<0.0001)
  • Drug treatments used
    • Hydroxychloroquine: 7% (40 patients)
    • Remdesivir: 3% (17 patients)
    • Lopinavir–ritonavir: 1% (6 patients)
    • Oseltamivir: 1% (3 patients)
  • Immunomodulatory medication used
    • Corticosteroids: 4% (22 patients)
    • Intravenous immunoglobulin: 1% (7 patients)
    • Tocilizumab: 1% (4 patients)
    • Anakinra: 1% (3 patients)
    • Siltuximab: <1% (1 patient)
  • Outcomes at study end
    • Died: 4 children
      • Case-fatality rate (CFR): 0.69% (95% CI 0.20 to 1.82)
    • Alive: 578 children
      • Still symptomatic or requiring respiratory support: 4% (25 patients)

CONCLUSION:

  • In this cohort of children, COVID-19 was generally mild
    • Multisystem Inflammatory Syndrome in Children (MIS-C) cases were being reported as this study went for publication
  • However, 8% of children developed severe disease requiring ICU admission
    • The greatest risk factors for ICU admission: <1 month | Male sex | Pre-existing medical conditions | Lower respiratory infection at presentation
  • and in addition, the authors state

Considering that many children with mild disease will never have been brought to medical attention, and therefore not diagnosed, it is highly probable that the true CFR is substantially lower than the figure of 0.69% observed in our cohort

Learn More – Primary Sources:

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

A Possible Explanation for Differing Rates of COVID-19 Infection between Adults and Children
Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19
Hyperinflammatory Shock in Children and COVID-19
NEJM Correspondence: Clinical Course of COVID-19 in Children

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site